You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Olaparib

Showing 26 - 50 of 385
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Tumors Trial run by the National Cancer Institute (NCI)

Recruiting
  • Gastroenteropancreatico Tumors
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

Recruiting
  • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
  • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
  • Montpellier, France
  • +1 more
Nov 16, 2022

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Olaparib
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 23, 2022

Breast Cancer Trial in Spain (Olaparib)

Terminated
  • Breast Cancer
  • Olaparib
  • Barcelona, Spain
  • +7 more
Jan 18, 2023

Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma Trial in Boston (Olaparib)

Not yet recruiting
  • Recurrent Metastatic Melanoma
  • +3 more
  • Olaparib
  • Boston, Massachusetts
  • +1 more
Jul 29, 2022

Chronic Lymphocytic Leukemia Trial in Salt Lake City (RP-3500 in combination with Olaparib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • RP-3500 in combination with Olaparib
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Sep 23, 2022

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York

Recruiting
  • Locally Advanced Leiomyosarcoma
  • +5 more
  • Olaparib
  • +3 more
  • New York, New York
    Columbia University/Herbert Irving Cancer Center
Jan 4, 2023

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

First-line Olaparib Combined With Bevacizumab Maintenance

Not yet recruiting
  • Ovarian Neoplasms
  • olaparib plus bevacizumab maintenance therapy
  • (no location specified)
Jun 29, 2022

Ovarian Cancer Trial in Birmingham (Carboplatin, olaparibp, embro)

Not yet recruiting
  • Ovarian Cancer
  • Birmingham, Alabama
    O'Neal Comprehensive Cancer Center at UAB
Jul 18, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)

Active, not recruiting
  • Laryngeal Cancer Stage II
  • +3 more
  • radiotherapy
  • Olaparib
  • Amsterdam, Netherlands
    The Netherlands Cancer Institute
Sep 27, 2022

Lung Cancer Trial in Korea, Republic of (Olaparib+Bevacizumab to SCLC patients)

Recruiting
  • Lung Cancer
  • Olaparib+Bevacizumab to SCLC patients
  • Seoul, Gangnam-gu, Korea, Republic of
  • +3 more
Nov 9, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Pembrolizumab
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Oct 25, 2022

Head Neck Cancer Trial in London, Wales (Olaparib, Cisplatin, IMRT)

Active, not recruiting
  • Head and Neck Cancer
  • Olaparib
  • +2 more
  • London, United Kingdom
  • +2 more
Nov 1, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)

Completed
  • Advanced Ovarian Cancer
  • Olaparib
  • Pegylated Liposomal Doxorubicin
  • Sabadell, Barcelona, Spain
  • +7 more
Jan 25, 2023

Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Olaparib
  • +4 more
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 13, 2023

Cervical Cancer Trial in Hidaka (Pembrolizumab, Olaparib)

Active, not recruiting
  • Cervical Cancer
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Aug 8, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Laboratory Biomarker Analysis, Olaparib,

Active, not recruiting
Has Results
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Laboratory Biomarker Analysis
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 19, 2022

High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)

Recruiting
  • High Grade Serous Carcinoma
  • +2 more
  • Toronto, Ontario, Canada
  • +2 more
Nov 28, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Endometrial Serous Adenocarcinoma
  • +2 more
  • Biopsy
  • +3 more
  • Phoenix, Arizona
  • +3 more
Feb 2, 2023